Source: CureToday articles
TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk non-muscle-invasive bladder cancer.
Recent Content
- A Dose of Inspiration: Celebrating the Pharmacist-Patient Relationship During Patient Experience Week
- Breast MRI Offers Sensitive Imaging for High-Risk and Diagnosed Patients
- Neoadjuvant Mitomycin C Shows Favorable Safety in Bladder Cancer
- AACR 2025: High Response Rates With Dostarlimab Suggest New Standard for dMMR Treatment
- How Mammogram Reminders Can Be More Thoughtful Following Breast Cancer
- AACR 2025: ctDNA Testing Identifies Recurrence Risk Within Weeks of Surgery in Colorectal Cancer
- AACR 2025: ctDNA-Guided Adjuvant PD-1 Blockade Shows Promise for Patients With Resected dMMR Solid Tumors
- TAR-200 Achieves High DFS and Bladder Preservation Rates in Bladder Cancer Subgroups
- Fellowship Focus: Elevating Pediatric Medication Safety Through Data, AI, and Collaboration
- Zongertinib Elicits Responses in HER2-Mutant NSCLC